Reuters logo
BRIEF-Syndax Pharmaceuticals announces advancement of encore 601
May 16, 2017 / 9:35 PM / 4 months ago

BRIEF-Syndax Pharmaceuticals announces advancement of encore 601

May 16 (Reuters) - Syndax Pharmaceuticals Inc:

* Syndax Pharmaceuticals announces advancement of encore 601 in non-small cell lung cancer patients with disease progression on or after PD-1 therapies

* Syndax Pharmaceuticals Inc - cohort of NSCLC patients who had previously progressed on PD-1 or PD-l1 will now re-open and enroll a total of 56 patients

* Syndax Pharmaceuticals Inc- completion of enrollment is anticipated in first half of 2018 for study

* Syndax Pharmaceuticals - later this quarter, co anticipates being able to determine whether to expand cohort of NSCLC patients naïve to PD-1 or PD-l1 therapy

* Syndax-Encore 601 non-small cell lung cancer study has met pre-specified objective response threshold to advance into 2nd stage of phase 2 trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below